Skip Navigation
Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

HIV/AIDS Therapeutics Clinical Research

Once a new therapeutic agent or strategy has been thoroughly studied in preclinical studies, the information generated typically is submitted to the Food and Drug Administration (FDA) as part of an Investigational New Drug (IND) application. Evaluation of the therapeutic agent or strategy in human subjects can begin once FDA has approved the IND application.

Clinical trials commonly are designed to investigate the safety and efficacy of new therapeutic agents for the treatment of HIV and its co-infections. The consequences of residual inflammation in virally suppressed individuals are also under investigation. The underlying pathogenic mechanisms are unknown or poorly understood. The potential for HIV eradication or long-term remission in the absence of HAART are also areas of intense research.

NIAID current research activities include the following:

  • NIAID funds grants to conduct clinical trials of new therapies or treatment regimens for treating HIV and its co-infections.
  • NIAID funds grants to evaluate approaches to prevent the transmission of HIV, improve and sustain an HIV-infected person’s immune function, overcome drug resistance, and eradicate HIV from latent tissue reservoirs.
  • NIAID funds grants to investigate the metabolic changes and complications associated with the use of HAART.
  • NIAID funds grants to evaluate therapeutic interventions aimed at HIV eradication or sustained remission.

Last Updated July 23, 2015